Drug Profile
Tifacogin
Alternative Names: LACI; SC 59735; TFP561; TFPI - Chiron/Pfizer; Tissue factor pathway inhibitor - Chiron/PfizerLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Chiron
- Developer Novartis
- Class Antithrombotics; Biological proteins
- Mechanism of Action Factor Xa inhibitors; Tissue factor-factor VIIa complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Community-acquired pneumonia; Reperfusion injury; Septic shock; Thrombosis
Most Recent Events
- 28 Jan 2009 Development discontinued for Community-acquired pneumonia during 2008
- 22 Apr 2008 Pharmacodynamics data from a preclinical trial against Escherichia coli infection (related to Community-acquired pneumonia) presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008)
- 22 May 2007 Tifacogin is still in active development